Lund, Sweden — 15 September 2021 — Camurus (NASDAQ STO: CAMX) today announced that Eva Pinotti-Lindqvist has decided to leave her position in the company. The company has initiated a process to recruit a successor. Eva has held her position in the company since June 2014 and will continue in her present role until a new CFO has been appointed.
“Eva has during her seven years as CFO with Camurus played an important role in the development of Camurus from a R&D based organization to a successful international pharmaceutical company,” says Fredrik Tiberg, President and CEO. “I would like to extend a warm thank you to Eva for her significant contribution to Camurus' positive development over the past seven years. Eva has been a dedicated and highly appreciated colleague and we wish her all the best when she now has decided to leave her position as CFO of the company.”
”I am grateful for having had the opportunity to serve as CFO and member of Camurus’ Executive Management Team and be part of a very positive and exciting period of the company’s development, including the IPO and successful launches of our first pharmaceutical product,” says Eva Pinotti-Lindqvist. ”Camurus has a great potential and is a fantastic organization and I am convinced that this is only the beginning of a successful growth journey."
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
This information was submitted for publication at 9:00 am CET on 15 September 2021.